Form 4: Bone Biologics Corp Director Acquires Stock Options

Robert E. Gagnon, a director of Bone Biologics Corp, reports the acquisition of stock options.

Summary

• Robert E. Gagnon, a director of Bone Biologics Corp, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of 30,713 non-employee stock options with an exercise price of $1.73, granted on September 17, 2024, and expiring on September 17, 2034.
• These options vest and become exercisable quarterly through the date of the next annual meeting of stockholders.
• Gagnon also holds other non-employee stock options with an exercise price of $4.68, totaling 8,015 shares, which are fully exercisable as of the report date.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. The director's acquisition could be seen as a positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Key Dates

Keywords

Form 4, Stock Options, Beneficial Ownership, Director, Bone Biologics Corp, BBLG